Sharp Therapeutics Corp. (TSXV:SHRX)

Canada flag Canada · Delayed Price · Currency is CAD
2.600
-0.750 (-22.39%)
At close: Dec 5, 2025
Market Cap 78.20M
Revenue (ttm) n/a
Net Income (ttm) -4.63M
Shares Out 30.08M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,700
Average Volume 3,723
Open 2.600
Previous Close 3.350
Day's Range 2.600 - 2.600
52-Week Range 0.230 - 5.000
Beta -1.47
RSI 47.13
Earnings Date Nov 28, 2025

About Sharp Therapeutics

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Scott Sneddon
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol SHRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.